Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 2;39(41):6111–6116. doi: 10.1016/j.vaccine.2021.08.078

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Immunological parameters of patients in response to COVID mRNA vaccines. A) Pre-vaccination IgM levels are lower in patients on BCDT. The p values are presented above the boxplots. P < 0.05 was considered significant. B) The time interval between infusion and vaccine, and total infusion therapy duration comparison between post-vaccination anti-spike positive and negative groups in patients on BCDT. A shorter time interval between infusion and vaccine was more likely to result in a negative antibody response. Comparisons were performed by Wilcoxon's two-sample test for continuous variables. The p values are presented above the boxplots. P < 0.05 was considered significant. C) Pre-vaccine percentage of CD19 and CD20 comparison between anti-spike positive and negative groups. For the comparison, the percentage of CD19 and CD20 levels were categorized as 0 (for values < 2%) and 1 (for values > 2%). Chi-Square test was used for categorical variables. Lower percentage levels of CD19 and CD 20 were seen for both pre- and post-vaccination in the anti-spike negative subgroup (non-seroconverter). Graphs shown are for pre vaccination data. The p values are presented above the boxplots. P < 0.05 was considered significant. D) Pre-vaccine absolute CD19 and CD20 (Abs) comparison between anti-spike positive and negative groups. CD19 Abs and CD20 Abs were categorized as 0 (for values < 20 cells/cmm) and 1 (for values > 20 cells/cmm). A Chi-Square test was used for categorical variables. Lower Abs CD19 and Abs CD20 levels were seen for both pre- and post-vaccination in the anti-spike negative subgroup (non-seroconverter). Graphs shown are for pre vaccination data. The p values are presented above the boxplots. P < 0.05 was considered significant. E) Post-vaccine IgG, IgA and IgM comparison between anti-spike antibody positive and negative groups. Lower IgG and IgA levels were seen post--vaccination anti-spike antibody negative group (non-seroconverter). Comparisons were performed by Wilcoxon's two-sample test for continuous variables. The p values are presented above the boxplots, and P < 0.05 was considered significant.